Literature DB >> 10790106

Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

J L Burns1, L Saiman, S Whittier, D Larone, J Krzewinski, Z Liu, S A Marshall, R N Jones.   

Abstract

Pseudomonas aeruginosa is the most common pathogen infecting the lungs of patients with cystic fibrosis (CF). Improved antimicrobial chemotherapy has significantly increased the life expectancy of these patients. However, accurate susceptibility testing of P. aeruginosa isolates from CF sputum may be difficult because the organisms are often mucoid and slow growing. This study of 597 CF isolates of P. aeruginosa examined the correlation of disk diffusion and Etest (AB BIODISK, Solna, Sweden) results with a reference broth microdilution method. The rates of interpretive errors for 12 commonly used antipseudomonal antimicrobials were determined. The disk diffusion method correlated well (zone diameter versus MIC) for all of the agents tested. However, for mucoid isolates, correlation coefficients (r values) for piperacillin, piperacillin-tazobactam, and meropenem were <0.80. The Etest correlation with reference broth microdilution results (MIC versus MIC) was acceptable for all of the agents tested, for both mucoid and nonmucoid isolates. Category interpretation errors were similar for the disk diffusion and Etest methods with 0.4 and 0.1%, respectively, very major errors (false susceptibility) and 1.1 and 2.2% major errors (false resistance). Overall, both agar diffusion methods appear to be broadly acceptable for routine clinical use in susceptibility testing of CF isolates of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10790106      PMCID: PMC86597     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

Review 1.  Management of pulmonary disease in patients with cystic fibrosis.

Authors:  B W Ramsey
Journal:  N Engl J Med       Date:  1996-07-18       Impact factor: 91.245

2.  Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.

Authors:  L Saiman; F Mehar; W W Niu; H C Neu; K J Shaw; G Miller; A Prince
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

3.  Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  R M Shawar; D L MacLeod; R L Garber; J L Burns; J R Stapp; C R Clausen; S K Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.

Authors:  L Saiman; J L Burns; S Whittier; J Krzewinski; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum.

Authors:  H R Stutman; J C Akaniro; C E Vidaurre; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

6.  Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; B Boxerbaum; R C Stern; P J Kuchenbrod
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

Review 7.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

8.  The changing epidemiology of cystic fibrosis.

Authors:  S C FitzSimmons
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

9.  Pseudomonas aeruginosa: biology, mechanisms of virulence, epidemiology.

Authors:  M L Vasil
Journal:  J Pediatr       Date:  1986-05       Impact factor: 6.314

10.  Biotinylated DNA probes for exotoxin A and pilin genes in the differentiation of Pseudomonas aeruginosa strains.

Authors:  M Samadpour; S L Moseley; S Lory
Journal:  J Clin Microbiol       Date:  1988-11       Impact factor: 11.677

View more
  29 in total

Review 1.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

2.  Compliance of clinical microbiology laboratories in the United States with current recommendations for processing respiratory tract specimens from patients with cystic fibrosis.

Authors:  Juyan Zhou; Elizabeth Garber; Manisha Desai; Lisa Saiman
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

3.  Accuracies of beta-lactam susceptibility test results for Pseudomonas aeruginosa with four automated systems (BD Phoenix, MicroScan WalkAway, Vitek, and Vitek 2).

Authors:  Stefan Juretschko; Vincent J Labombardi; Stephen A Lerner; Paul C Schreckenberger
Journal:  J Clin Microbiol       Date:  2007-01-17       Impact factor: 5.948

4.  Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.

Authors:  María Díez-Aguilar; María Isabel Morosini; Emin Köksal; Antonio Oliver; Miquel Ekkelenkamp; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Performance of Vitek 2 in antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates with different mechanisms of beta-lactam resistance.

Authors:  Annarita Mazzariol; Marco Aldegheri; Marco Ligozzi; Giuliana Lo Cascio; Raffaella Koncan; Roberta Fontana
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

6.  Validation of Vitek 2 nonfermenting gram-negative cards and Vitek 2 version 4.02 software for identification and antimicrobial susceptibility testing of nonfermenting gram-negative rods from patients with cystic fibrosis.

Authors:  Ines Otto-Karg; Stefanie Jandl; Tobias Müller; Beate Stirzel; Matthias Frosch; Helge Hebestreit; Marianne Abele-Horn
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

7.  Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia.

Authors:  Samuel M Moskowitz; Elizabeth Garber; Yunhua Chen; Sarah A Clock; Setareh Tabibi; Amanda K Miller; Michael Doctor; Lisa Saiman
Journal:  J Antimicrob Chemother       Date:  2010-04-29       Impact factor: 5.790

8.  Susceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward?

Authors:  Shawn Vasoo
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

9.  Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

Authors:  María I Morosini; María García-Castillo; Elena Loza; María Pérez-Vázquez; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

10.  Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  Samuel M Moskowitz; Jessica M Foster; Julia Emerson; Jane L Burns
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.